Logo Logo
Switch Language to German
Ibanez, Luisa; Sabate, Monica; Vidal, Xavier; Ballarin, Elena; Rottenkolber, Marietta; Schmiedl, Sven; Heeke, Andreas; Huerta, Consuelo; Martin Merino, Elisa; Montero, Dolores; Maria Leon-Munoz, Luz; Gasse, Christiane; Moore, Nicholas; Droz, Cecile; Lassalle, Regis; Aakjaer, Mia; Andersen, Morten; De Bruin, Marie Louise; Groenwold, Rolf; van den Ham, Hendrika A.; Souverein, Patrick; Klungel, Olaf; Gardarsdottir, Helga (2019): Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study. In: British Journal of Clinical Pharmacology, Vol. 85, No. 11: pp. 2524-2539
Full text not available from 'Open Access LMU'.


Aims To estimate the incidence of direct oral anticoagulant drug (DOAC) use in patients with nonvalvular atrial fibrillation and to describe user and treatment characteristics in 8 European healthcare databases representing 6 European countries. Methods Longitudinal drug utilization study from January 2008 to December 2015. A common protocol approach was applied. Annual period incidences and direct standardisation by age and sex were performed. Dose adjustment related to change in age and by renal function as well as concomitant use of potentially interacting drugs were assessed. Results A total of 186 405 new DOAC users (age >= 18 years) were identified. Standardized incidences varied from 1.93-2.60 and 0.11-8.71 users/10 000 (2011-2015) for dabigatran and rivaroxaban, respectively, and from 0.01-8.12 users/10 000 (2012-2015) for apixaban. In 2015, the DOAC incidence ranged from 9 to 28/10 000 inhabitants in SIDIAP (Spain) and DNR (Denmark) respectively. There were differences in population coverage among the databases. Only 1 database includes the total reference population (DNR) while others are considered a population representative sample (CPRD, BIFAP, SIDIAP, EGB, Mondriaan). They also varied in the type of drug data source (administrative, clinical). Dose adjustment ranged from 4.6% in BIFAP (Spain) to 15.6% in EGB (France). Concomitant use of interacting drugs varied between 16.4% (SIDIAP) and 70.5% (EGB). Cardiovascular comorbidities ranged from 25.4% in Mondriaan (The Netherlands) to 82.9% in AOK Nordwest (Germany). Conclusion Overall, apixaban and rivaroxaban increased its use during the study period while dabigatran decreased. There was variability in patient characteristics such as comorbidities, potentially interacting drugs and dose adjustment. (EMA/2015/27/PH).